Clinical trials
Prostate Cancer Stage clinical trials
Below are recruiting prostate cancer stage clinical trials, each written for real people, not researchers. We’re tracking 408 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06178354Recruiting
Freezing or ultrasound for early prostate cancer
This trial is testing whether freezing (cryotherapy) or using high-frequency ultrasound (HIFU) to destroy only the cancer spots in the prostate is safe and effective for men with early-stage prostate cancer. It's a less invasive option that targets just the tumor, not the whole prostate.
Sacramento, CaliforniaAges 18 years+ - NCT02172651RecruitingEarly Phase 1
Vitamin D during early colon cancer or liver surgery
This trial studies whether taking higher-dose vitamin D3 around the time of colon cancer (or colon cancer with resectable liver metastases) surgery improves outcomes. It focuses on safety and possible effects on cancer-related health after surgery.
Boston, MassachusettsAges 18 years+ - NCT07398690Recruiting
MRI-guided approach for prostate cancer diagnosis
This trial tests if using MRI and a blood test called PHI can help decide who needs a prostate biopsy. It aims to avoid unnecessary biopsies while still catching cancer early.
SeoulAges 20 years+ - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07468903Recruiting
Focal radiation for prostate cancer with HDR brachytherapy
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Los Angeles, CaliforniaAges 40 years+ - NCT07223385RecruitingPhase 2
Heart health check for prostate cancer patients on ARPI therapy
This trial is for men with advanced prostate cancer who are taking ARPI therapy. It offers a special heart health consultation to help manage the increased heart risk that can come with these powerful cancer treatments.
Los Angeles, CaliforniaAges 45 years+ - NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT07635238RecruitingPhase 2
Lower Dose Radiation for Prostate Cancer
This trial tests whether a lower dose of radiation can effectively treat prostate cancer while reducing side effects. It is for men with certain types of prostate cancer that are visible on an MRI.
Basking Ridge, New JerseyAges 18 years+ - NCT06505356Enrolling by invitation
Genetics and inflammation in prostate cancer stage
This study looks at the connection between genetics, inflammation, and prostate cancer stage. It aims to find markers that may help predict how aggressive the cancer is. You may be eligible if you are newly suspected of having prostate cancer and have not yet started treatment.
KaunasAges 18–100 - NCT06325774Recruiting
Shorter radiation for localized prostate cancer
This trial tests a shorter, more intense course of radiation (hypofractionated radiotherapy) for men with localized prostate cancer that hasn't spread. It aims to see if this treatment is safe and effective and may reduce the number of hospital visits.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05010343RecruitingPhase 2
Carbon ion radiation guided by scans for prostate cancer
This Phase 2 trial tests whether using detailed scans (PSMA PET/CT and MRI) to guide carbon ion radiation—delivered in a focused way—can treat localized prostate cancer. It may help target the treatment more precisely while avoiding areas that are not involved.
ShanghaiAges 45–85 - NCT04086290RecruitingPhase 1/Phase 2
Surgery plus targeted radiation for prostate cancer spread
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
HerlevAges 18 years+ - NCT06362577Recruiting
HIFU vs Robot Surgery for Localized Prostate Cancer
This trial compares two treatments for localized prostate cancer: high-intensity focused ultrasound (HIFU) using a device called Sonablate and robot-assisted surgery. It aims to see which works better and has fewer side effects.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT06325995Recruiting
Short radiation course after prostate surgery for rising PSA
This trial tests a shorter, stronger course of radiation (hypofractionated radiotherapy) given after prostate removal surgery. It may help people whose PSA levels rise again after surgery, aiming to reduce side effects and improve outcomes.
Shanghai, Shanghai MunicipalityAges Any age - NCT03322891Recruiting
Helping African-American men understand prostate cancer care
This study tests an approach to improve health understanding for African-American patients with early-stage prostate cancer. It may help you communicate better with your care team and feel more confident managing your diagnosis and next steps.
Atlanta, GeorgiaAges 25–100 - NCT03408964Recruiting
Blood tests to predict treatment response in prostate cancer
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
BellinzonaAges 18 years+ - NCT05616650RecruitingPhase 2
Targeted radiation for one prostate tumor spot
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
Bethesda, MarylandAges 18–120 - NCT05790213RecruitingPhase 2
Hormone therapy plus targeted prostate treatment for intermediate cancer
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Chicago, IllinoisAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06776172Recruiting
Lymph node removal during prostate surgery: a comparison study
This trial tests whether removing pelvic lymph nodes during prostate cancer surgery improves outcomes for men with high-risk prostate cancer. If you have high-risk prostate cancer and no signs of spread, you may be able to join.
AarauAges 18 years+ - NCT07056790RecruitingPhase 1/Phase 2
PET scan using 68Ga-PSMA-CYC for prostate cancer
This trial is testing a new type of PET scan that uses a special tracer called 68Ga-PSMA-CYC to take detailed pictures of prostate cancer. It may help doctors better see where the cancer is and how far it has spread.
Fuzhou, FujianAges 18–80
Hear when a new Prostate Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer stage?
- Yes. Clin2 currently lists 408 recruiting prostate cancer stage studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer stage trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer stage trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.